A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours

European Journal of Cancer

Volumn 49, Issue 4, 2013, Pages 782-789

  MacPherson, I R ^a   Poondru, S ^b   Simon, G R ^c   Gedrich, R ^b   Brock, K ^b   Hopkins, C A ^a   Stewart, K ^a   Stephens, A ^b   Evans, T R J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b OSI Pharmaceuticals LLC   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Combination; Erlotinib; Pharmacodynamics; Pharmacokinetics; Phase I; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; ERLOTINIB; OSI 930; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; ASTHENIA; BODY WEIGHT; CANCER PATIENT; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; DERMATITIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ERUPTION; DYSGEUSIA; DYSPEPSIA; FEMALE; HAIR COLOR; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LETHARGY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA AND VOMITING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; STOMATITIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; QUINOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; THIOPHENES; TISSUE DISTRIBUTION;

EID: 84873713604     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.09.036     Document Type: Article

References (24)

1. J. Tabernero The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents Mol Cancer Res 5 3 2007 203 220
2. A.M. Petit, J. Rak, and M.C. Hung Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors Am J Pathol 151 6 1997 1523 1530
3. F. Riedel, K. Gotte, M. Li, K. Hormann, and J.R. Grandis EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration Int J Oncol 21 1 2002 11 16
4. A. Viloria-Petit, T. Crombet, and S. Jothy Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis Cancer Res 61 13 2001 5090 5101
5. F. Ciardiello, R. Bianco, and R. Caputo Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy Clin Cancer Res 10 2 2004 784 793
6. R. Bianco, R. Rosa, and V. Damiano Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells Clin Cancer Res 14 16 2008 5069 5080
7. G.N. Naumov, M.B. Nilsson, and T. Cascone Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance Clin Cancer Res 15 10 2009 3484 3494
8. T. Cascone, M.H. Herynk, and L. Xu Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma J Clin Invest 121 4 2011 1313 1328
9. R.S. Herbst, R. Ansari, and F. Bustin Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial Lancet 377 9780 2011 1846 1854
10. J. Tol, M. Koopman, and A. Cats Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 6 2009 563 572
11. J.R. Hecht, E. Mitchell, and T. Chidiac A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol 27 5 2009 672 680
12. J. Lee, V. Hirsh, and K. Park Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): a randomized, double-blind phase III trial (ZEPHYR) J Clin Oncol 28s 2010 abstr. 7525
13. R.B. Natale, S. Thongprasert, and F.A. Greco Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer J Clin Oncol 29 8 2011 1059 1066
14. R.S. Herbst, Y. Sun, and W.E. Eberhardt Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial Lancet Oncol 11 7 2010 619 626
15. R.H. de Boer, O. Arrieta, and C.H. Yang Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial J Clin Oncol 29 8 2011 1067 1074
16. A.J. Garton, A.P. Crew, and M. Franklin OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models Cancer Res 66 2 2006 1015 1024
17. S. George, R. Lal, and D.R. Camidge Final results of a dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of two schedules of OSI-930 in patients (pts) with advanced solid tumors J Clin Oncol 27s 2009 abstr. 3564
18. M. Rosenfeld-Franklin, S. Silva, and C. Pirritt Antitumor efficacy of OSI-930 and the molecular targeted agent erlotinib in preclinical xenograft models J Clin Oncol 26s 2008 abstr. 14596
19. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205 216
20. M. Hidalgo, L.L. Siu, and J. Nemunaitis Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies J Clin Oncol 19 13 2001 3267 3279
21. J.-F. Lu, S.M. Eppler, and J. Wolf Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer Clin Pharmacol Ther 80 2 2006 136 145
22. F.A. Shepherd, J. Rodrigues Pereira, and T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2 2005 123 132
23. H.L. Lin, H.M. Zhang, C. Medower, P.F. Hollenberg, and W.W. Johnson Inactivation of cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a thiophene-containing anticancer drug Drug Metab Dispos 39 2 2011 345 350
24. D.R. Duckett, and M.D. Cameron Metabolism considerations for kinase inhibitors in cancer treatment Expert Opin Drug Metab Toxicol 6 10 2010 1175 1193